Market News & Trends
Symbiosis Pharmaceutical Services Granted MHRA License Following Significant Investment
Symbiosis Pharmaceutical Services has recently launched new in-house analytical and microbiological capabilities to enable testing of small molecule, biological, and Advanced Therapeutic Medicinal Products (ATMP)…
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
Zevra Therapeutics, Inc. recently announced the completion of its acquisition of Acer Therapeutics Inc., which marks a significant step forward in executing Zevra’s strategy to become….
Hovione Acquires ExtremoChem & Its Portfolio of Proprietary Sugars to Support Customers With Stabilization & Delivery of Biopharmaceuticals
Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, has recently announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on….
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to EMA
Anavex Life Sciences Corp. recently announced representatives of Anavex met with team members of the European Medicines Agency (EMA). These meetings discussed the debilitating pathology…
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
Yamo Pharmaceuticals LLC recently announced it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder…
Boehringer Ingelheim Expands Usage of Genedata Biologics to DMPK Operations
Genedata recently announced Boehringer Ingelheim has expanded usage of the Genedata platform to include the Drug Metabolism and Pharmacokinetics (DMPK) group in the US. The…
Medicenna Announces Compelling Survival Benefit From Phase 2b Study of Bizaxofusp in Recurrent Gliobastoma
Medicenna Therapeutics Corp. recently announced a poster presentation and an oral summary highlighting longer term follow up results from the Phase 2b clinical trial of…
Uppsala University Hospital & Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients With Type 1 Diabetes
Sana Biotechnology, Inc. and Uppsala University Hospital in Sweden recently announced the Swedish Medical Products Agency has authorized Uppsala University’s Clinical Trial Application (CTA) to…
Ichor Life Sciences Announces Launch of Ichor Clinical Trial Services
Ichor Life Sciences recently announced the launch of Ichor Clinical Trial Services. With the founding of Ichor Clinical, the company is now able to serve…
Ajinomoto to Acquire Forge Biologics for $620 Million
Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services….
Symbio & Dow Group Merge With Proinnovera to Form Leading Dermatology CRO, Symbio Proinnovera
The newly announced merger of NY-headquartered Symbio LLC and CA-headquartered Dow Development Laboratories LLC with Munster (Germany)-based Proinnovera will form Symbio Proinnovera, creating one of…
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics Inc. recently announced its partner in China, Avistone Biotechnology Co. Ltd., received conditional approval from the National Medical Products Administration (NMPA) of China for…
Prange Group & Adragos Pharma to Acquire Fresenius Kabi’s Manufacturing Site
Prange Group and its affiliate Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi for the acquisition of the leading sterile pharmaceutical production site in….
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
Mural Oncology plc recently launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop….
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
Evaxion Biotech A/S recently presented for the first time its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision…
SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases
SciRhom GmbH recently announced the achievement of a significant milestone in its development pipeline. The company has submitted a Clinical Trial Application for its lead…
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human SQ Dosing Option for Patients With Alpha1-Antitrypsin Deficiency
Grifols recently announced it has completed Cohort 1 of its Phase 1/2 study (NCT04722887) evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), a subcutaneous (SQ)…
Absci & Almirall Announce AI Drug Discovery Partnership to Rapidly Develop Novel Treatments for Dermatological Diseases
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases….
Amydis Receives $3.4-Million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer
Amydis Inc. recently announced it has received a 2-year Commercialization Readiness Pilot (CRP) Program grant award of $3.4 million from The National Institutes of Health.…
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals
QSAM Biosciences Inc. has signed a non-binding term sheet with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited providing material terms for the acquisition of the company by….
